Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

gpIIb/IIIa antagonist selected for clinical evaluation at DuPont Merck

Sep. 27, 1996

DuPont Merck proposes new standards for warfarin products

Sep. 27, 1996

Thrombin inhibitors with improved selectivity from Servier

Sep. 27, 1996

Antiplatelet ketoprofen analogue from Fuji Chem.

Sep. 20, 1996

Bristol-Myers Squibb to acquire prostacyclin analogue for claudication

Sep. 20, 1996

New prostacyclins from Asahi Glass

Sep. 20, 1996

Anticoagulant for treating blood clots approved in Canada

Sep. 20, 1996

R&D in blood coauglation at Daiichi

Sep. 13, 1996

Review on gpIIb/IIIa antagonists for ischemic complications

Sep. 13, 1996

Antiplatelet agents reported by Lilly

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...